We discussed TLX in our Q&A report a few weeks ago, while it may be on hold for a while as the FDA reviews its promising imaging tool for brain cancer, Pixclara, this could afford an ideal opportunity for patient investors to accumulate TLX. To put the company’s growth into perspective, revenue increased by over 50% from 2023 to $783mn in 2024, with a whopping $1.6bn forecast for 2026, with the company enjoying significant margins before R&D expenditure on future growth.
- We believe TLX is a world-class company, and its volatility is useful for investors looking to establish a position – this is one we are watching closely.
MM is cautiously bullish on TLX in the $21-24 region
Add To Hit List
